Related Experiment Videos
Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates
1Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Co., Lilly Corporate Center, Indianapolis, Indiana, USA.
The Journal of Pharmacology and Experimental Therapeutics
|September 22, 1999
Summary
Researchers developed a 3D-quantitative structure-activity relationship model for cytochrome P-450 (CYP) 3A4 substrates. This model accurately predicts substrate metabolism, aiding drug development and understanding enzyme interactions.
Area of Science:
- Pharmacology
- Medicinal Chemistry
- Computational Chemistry
Background:
- Cytochrome P-450 (CYP) 3A4 is a key enzyme in drug metabolism.
- Understanding its active site is crucial for predicting drug interactions and efficacy.
Purpose of the Study:
- To construct a 3D-quantitative structure-activity relationship (3D-QSAR) model for CYP3A4 substrates.
- To identify key pharmacophoric features of CYP3A4 substrates and activators.
- To evaluate the predictive power of the model for in silico drug design.
Main Methods:
- A 3D-QSAR pharmacophore model was built using 38 CYP3A4 substrates and their K(m (apparent)) values.
- The model incorporated features like hydrogen bond acceptors/donors and hydrophobic regions.
- Model validity was assessed through randomization and prediction on an independent test set.
Main Results:
- The developed pharmacophore model showed a good fit (r=0.67) for observed and predicted K(m (apparent)) values.
- The 'fast fit' algorithm in Catalyst accurately predicted K(m (apparent)) for 12 diverse CYP3A4 substrates (residual <1 log unit).
- A separate pharmacophore model for CYP3A4 activators indicated multiple hydrophobic regions.
Conclusions:
- The 3D-QSAR model effectively represents features of CYP3A4 substrates.
- The 'fast fit' method in Catalyst provides reliable in silico predictions for CYP3A4 substrate activity.
- CYP3A4 activators may interact with a distinct region of the enzyme's active site.